Estratègies d'intervenció i avaluació de l'hàbit tabàquic

Objectiu: Donar informació sobre els riscos del tabac, avaluar l’hàbit tabàquic i el compliment de la normativa vigent per part de la comunitat universitària a través d’una campanya de sensibilització. Metodologia: Prèviament a l’inici de les activitats es van dissenyar i passar unes enquestes per avaluar l’hàbit tabàquic als estudiants (a l’aula) i treballadors de l’Escola de Ciències de la Salut. Durant la setmana d’activitats, que coincidia amb el Dia Internacional de LLuita Antitabàquica, es va crear una taula informativa a càrrec dels estudiants de l’assignatura Atencions d’Infermeria a Addiccions i Toxicomanies, per tal d’informar de forma àmplia sobre el tabaquisme, conseqüències i tractaments. Al mateix temps i de forma passiva en uns monitors de TV es donava més informació, amb una material creat per aquesta campanya. Resultats: Els mitjans de comunicació van demostrar, des de l’inici de la campanya, un gran interès. Respecte a la participació per part de la comunitat universitària podem dir que va ser acceptable, al voltant de 1000 persones van passar per la taula informativa. El perfil dels estudiants que van contestar l’enquesta va ser dona (66.4%), alumne de fisioteràpia (49%), fumadors (regulars i ocasionals 52%). Dintre del grup de fumadors regulars per gèneres les dones fumen més 37%, front als homes 27.7%. Consum setmanal de cigarretes (regulars i ocasionals), presenta una mitjana de 59 (D.E=49). La majoria ha fet algun intent de deixar de fumar, 61%. Respecte al temps d’ abstinència un 69.9% no ha passat de 3 mesos i un 96% pensa que fumar en un espai tancat és perjudicial pels altres. Per últim, de tots el entrevistats la gran majoria (97.8%), declaren que fumen davant seu i a un 41.4 % els molesta. Conclusions: La Comissió fa una valoració positiva general, de com es van desenvolupar les diferents activitats. No obstant s’observa poca sensibilització per una part de la comunitat universitària respecte a la llibertat de viure

Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial

No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19.The authors thank Gerard Carot-Sans, PhD, for providing medical writing support during the revisions of the subsequent drafts of the manuscript; the personnel from the Fights Aids and Infectious Diseases Foundation for their support in administration, human resources and supply chain management; Eric Ubals (Pierce AB) and Òscar Palao (Opentic) for website and database management; Óscar Camps and OpenArms nongovernmental organization for nursing home operations; and Anna Valentí and the Hospital Germans Trias i Pujol Human Resources Department for telephone monitoring. We thank Consorci Sanitari del Maresme, Centre Sociosanitari El Carme, l'Hospital General de Granollers and occupational hazards department of Hospital Germans Trias i Pujol for their contribution with patient enrollment. We are very grateful to Marc Clotet and Natalia Sánchez who coordinated the JoEmCorono crowd-funding campaign. We thank the Hospital Germans Trias Pujol Institutional Review Board and the Spanish Agency of Medicines and Medical Devices for their prompt action for consideration and approvals to the protocol. Financial support. This work was mainly supported by the crowd-funding campaign JoEmCorono (https://www.yomecorono.com/) with contributions from more than 72 000 citizens and corporations. The study also received financial support from Laboratorios Rubió, Laboratorios Gebro Pharma, Zurich Seguros, SYNLAB Barcelona, and Generalitat de Catalunya. Laboratorios Rubió also contributed to the study with the required doses of hydroxychloroquine (Dolquine®). Foundation Dorneur partly funded lab equipment at Irsi-Caixa.Peer reviewe

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when = 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution